Cargando…

Role of dexmedetomidine infusion after coronary artery bypass grafting

BACKGROUND: Postoperative pain has negative consequences on patients’ outcomes after cardiac surgery. Routine management with opioid and or non-steroidal anti-inflammatory medications has several disadvantages. Dexmedetomidine is a selective α2 agonist used for sedation and analgesia. The use of dex...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamouda, Tamer, Ismail, Mohamed, Ibrahim, Tamer Hamed, Ewila, Hesham, Elmahrouk, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223605/
http://dx.doi.org/10.1186/s43057-019-0014-8
_version_ 1783533771214028800
author Hamouda, Tamer
Ismail, Mohamed
Ibrahim, Tamer Hamed
Ewila, Hesham
Elmahrouk, Ahmed
author_facet Hamouda, Tamer
Ismail, Mohamed
Ibrahim, Tamer Hamed
Ewila, Hesham
Elmahrouk, Ahmed
author_sort Hamouda, Tamer
collection PubMed
description BACKGROUND: Postoperative pain has negative consequences on patients’ outcomes after cardiac surgery. Routine management with opioid and or non-steroidal anti-inflammatory medications has several disadvantages. Dexmedetomidine is a selective α2 agonist used for sedation and analgesia. The use of dexmedetomidine for postoperative pain management and decreasing delirium and agitation in cardiac surgery patients is a matter of debate. Our objective was to determine the role of an early administration of dexmedetomidine in decreasing opioid use post-cardiac surgery and its effects on the quality of postoperative recovery. RESULTS: Medical records of 120 patients admitted to the cardiac surgery intensive care unit (CSICU) after coronary artery bypass grafting (CABG) in two cardiac centers between December 2015 and December 2016 were reviewed. Patients were divided into two groups. Group A included 55 patients who received dexmedetomidine in a dose of 0.2–0.4 mcg/kg/h on admission to CSICU, and group B included 65 patients who did not receive dexmedetomidine. The primary outcome was the pain score immediately after extubation, and the secondary outcomes included post-extubation sedation and pain scores for 12 h. There were significant decrease of the pain scores in dexmedetomidine group that continues through the 3rd, 6th, 8th, and 12th hour readings after surgery with mean modified Ramsay scores 0.1 ± 0.0, 0.89 ± 2.05, 0.35 ± 0.1, and 0.12 ± 1.1 respectively compared to 0.46 ± 1.15, 3.46 ± 2.93, 0.98 ± 1.90, and 0.12 ± 1.1 in group B (p < 0.001), significant decrease in cumulative morphine received (p < 0.001, OR = 909, 95% CI 0.05–0.19), favorable reduction in heart rate in dexmedetomidine group (80 ± 1.9 b/min) compared to 96 ± 8.8 b/min in the other group (p = 0.017), and smoother recovery from general anesthesia. CONCLUSION: Administration of dexmedetomidine in the early postoperative period can be safe. It may reduce the use of opioids, has sedative, analgesic, and sympatholytic effects that could play a useful role during the management of coronary artery bypass patients, and may improve postoperative recovery.
format Online
Article
Text
id pubmed-7223605
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72236052020-05-15 Role of dexmedetomidine infusion after coronary artery bypass grafting Hamouda, Tamer Ismail, Mohamed Ibrahim, Tamer Hamed Ewila, Hesham Elmahrouk, Ahmed Cardiothorac Surg Research BACKGROUND: Postoperative pain has negative consequences on patients’ outcomes after cardiac surgery. Routine management with opioid and or non-steroidal anti-inflammatory medications has several disadvantages. Dexmedetomidine is a selective α2 agonist used for sedation and analgesia. The use of dexmedetomidine for postoperative pain management and decreasing delirium and agitation in cardiac surgery patients is a matter of debate. Our objective was to determine the role of an early administration of dexmedetomidine in decreasing opioid use post-cardiac surgery and its effects on the quality of postoperative recovery. RESULTS: Medical records of 120 patients admitted to the cardiac surgery intensive care unit (CSICU) after coronary artery bypass grafting (CABG) in two cardiac centers between December 2015 and December 2016 were reviewed. Patients were divided into two groups. Group A included 55 patients who received dexmedetomidine in a dose of 0.2–0.4 mcg/kg/h on admission to CSICU, and group B included 65 patients who did not receive dexmedetomidine. The primary outcome was the pain score immediately after extubation, and the secondary outcomes included post-extubation sedation and pain scores for 12 h. There were significant decrease of the pain scores in dexmedetomidine group that continues through the 3rd, 6th, 8th, and 12th hour readings after surgery with mean modified Ramsay scores 0.1 ± 0.0, 0.89 ± 2.05, 0.35 ± 0.1, and 0.12 ± 1.1 respectively compared to 0.46 ± 1.15, 3.46 ± 2.93, 0.98 ± 1.90, and 0.12 ± 1.1 in group B (p < 0.001), significant decrease in cumulative morphine received (p < 0.001, OR = 909, 95% CI 0.05–0.19), favorable reduction in heart rate in dexmedetomidine group (80 ± 1.9 b/min) compared to 96 ± 8.8 b/min in the other group (p = 0.017), and smoother recovery from general anesthesia. CONCLUSION: Administration of dexmedetomidine in the early postoperative period can be safe. It may reduce the use of opioids, has sedative, analgesic, and sympatholytic effects that could play a useful role during the management of coronary artery bypass patients, and may improve postoperative recovery. Springer Berlin Heidelberg 2020-01-22 2020 /pmc/articles/PMC7223605/ http://dx.doi.org/10.1186/s43057-019-0014-8 Text en © The Author(s) 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Hamouda, Tamer
Ismail, Mohamed
Ibrahim, Tamer Hamed
Ewila, Hesham
Elmahrouk, Ahmed
Role of dexmedetomidine infusion after coronary artery bypass grafting
title Role of dexmedetomidine infusion after coronary artery bypass grafting
title_full Role of dexmedetomidine infusion after coronary artery bypass grafting
title_fullStr Role of dexmedetomidine infusion after coronary artery bypass grafting
title_full_unstemmed Role of dexmedetomidine infusion after coronary artery bypass grafting
title_short Role of dexmedetomidine infusion after coronary artery bypass grafting
title_sort role of dexmedetomidine infusion after coronary artery bypass grafting
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223605/
http://dx.doi.org/10.1186/s43057-019-0014-8
work_keys_str_mv AT hamoudatamer roleofdexmedetomidineinfusionaftercoronaryarterybypassgrafting
AT ismailmohamed roleofdexmedetomidineinfusionaftercoronaryarterybypassgrafting
AT ibrahimtamerhamed roleofdexmedetomidineinfusionaftercoronaryarterybypassgrafting
AT ewilahesham roleofdexmedetomidineinfusionaftercoronaryarterybypassgrafting
AT elmahroukahmed roleofdexmedetomidineinfusionaftercoronaryarterybypassgrafting